Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population

Brandi Handel, MSN, RN, Nicole McEntee, BSN, RN, OCN, BMTCN, Anne Tyno, RN, MSN, APN-C, Patricia Andrews, BSN, RN, OCN, Patricia Lafaro, BS, RN, CIC, Vimal Patel, MD, Dale G Schaar, MD PhD, Roger Strair, MD PhD, Dennis Cooper, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142972

Published: 2020

Journal Articles

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Dennis Cooper, MD, Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD PhD, Tracy Krimmel, AOCN, APRN-BC, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 4485.

https://doi.org/10.1182/blood-2019-130598

Published: 2019

Journal Articles

Deep DNA Sequencing Identifies Small Mutations in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Analysis of Intratumor Genomic Heterogeneity for Prediction of Disease Relapse

Athena Kritharis, MD, Sukhdeep Kaur, MD, Jui Wan Loh, BS, Mohammad Hadigol, PhD, Hossein Khiabanian, PhD, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 1445.

https://doi.org/10.1182/blood-2019-126303

Published: 2019

Journal Articles

Probiotic Enteric Regimen for Easing the Complications of Transplant

Elan Gorshein, DO, Susan Ambrosy, Shanna Budney, Juliana Vivas, Jacqueline Manago, Mary Kate McGrath, Anne Tyno, Roger Strair, MD PhD

Blood (2014) 124 (21): 5877.

https://doi.org/10.1182/blood.V124.21.5877.5877

Published: 2014

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Blood (2012) 120 (21): 675.

https://doi.org/10.1182/blood.V120.21.675.675

Published: 2012

Journal Articles

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Swaminathan Padmanabhan, MD, Roger Strair, MD, Mark Kirschbaum, MD, Peter Maslak, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Susan O'Brien, Felipe Samaniego, Gautam Borthakur, MD, Marina Konopleva, MD, PhD, Lyubomir Vassilev, PhD, Gwen Nichols, MD

Blood (2010) 116 (21): 657.

https://doi.org/10.1182/blood.V116.21.657.657

Published: 2010

Journal Articles

On Being Duped: Duplication of Chromosome 1 [Dup(1)(q21q32)] as the Sole Cytogenetic Abnormality In a Patient Previously Treated for AML

Douglas F. Beach, MD, Barry Barnoski, PhD, FACMG, Vimal Patel, MD, Roland Schwarting, MD, Roger Strair, MD, PhD, Neil A. Lachant, MD

Blood (2010) 116 (21): 4863.

https://doi.org/10.1182/blood.V116.21.4863.4863

Published: 2010

Journal Articles

Identification and Modeling of TEL-AML1 ( ETV6 - RUNX1 ) Molecular Signature In Acute Lymphoblastic Leukemia

Gregory Miles, Gunaretnam Rajagopal, PhD, Roger Strair, MD, Hatem E Sabaawy, MD, PhD

Blood (2010) 116 (21): 2500.

https://doi.org/10.1182/blood.V116.21.2500.2500

Published: 2010

Journal Articles

Irradiated Third Party Peripheral Blood Mononuclear Cells Enhance Umbilical Cord Blood Engraftment.

Tulin Budak-Alpdogan, MD, Gajan Jeganathan, Kuo-Chieh Lee, M.D., Zbigniew Roger Mrowiec, Ph.D., Daniel Medina, Ph.D., Dennis Todd, Ph.D., Dirk Moore, Ph.D., Joseph Bertino, MD, Roger Strair, MD, PhD

Blood (2009) 114 (22): 3533.

https://doi.org/10.1182/blood.V114.22.3533.3533

Published: 2009

Journal Articles

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Blood (2004) 104 (11): 4640.

https://doi.org/10.1182/blood.V104.11.4640.4640

Published: 2004

Journal Articles

Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.

Stephen M. Ansell, MD, PhD, John C. Byrd, MD, Steven M. Horwitz, MD, Peter Borchmann, MD, Andreas Engert, MD, Roger Strair, MD, Khuda D. Khan, MD, Steven A. Fischkoff, MD, Michael Yellin, MD

Blood (2004) 104 (11): 2636.

https://doi.org/10.1182/blood.V104.11.2636.2636

Published: 2004

NARROW

Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Deep DNA Sequencing Identifies Small Mutations in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Analysis of Intratumor Genomic Heterogeneity for Prediction of Disease Relapse

Probiotic Enteric Regimen for Easing the Complications of Transplant

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

On Being Duped: Duplication of Chromosome 1 [Dup(1)(q21q32)] as the Sole Cytogenetic Abnormality In a Patient Previously Treated for AML

Identification and Modeling of TEL-AML1 ( ETV6 - RUNX1 ) Molecular Signature In Acute Lymphoblastic Leukemia

Irradiated Third Party Peripheral Blood Mononuclear Cells Enhance Umbilical Cord Blood Engraftment.

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only